Hydrochlorothiazide
- Generic Name
- Hydrochlorothiazide
- Brand Names
- Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac
- Drug Type
- Small Molecule
- Chemical Formula
- C7H8ClN3O4S2
- CAS Number
- 58-93-5
- Unique Ingredient Identifier
- 0J48LPH2TH
- Background
Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II rec...
- Indication
Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.
- Associated Conditions
- Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke
- Associated Therapies
- -
Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension
- Conditions
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 480
- Registration Number
- NCT00425997
- Locations
- 🇺🇸
Sites in USA, East Hanover, New Jersey, United States
An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2011-03-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 556
- Registration Number
- NCT00402103
- Locations
- 🇩🇪
Investigative Center, Investigative Center, Germany
🇧🇪Investigator Site, Investigative Site, Belgium
🇨🇭Investigative Site, Investigative Site, Switzerland
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg
- Conditions
- Interventions
- First Posted Date
- 2006-10-04
- Last Posted Date
- 2008-03-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1979
- Registration Number
- NCT00383929
- Locations
- 🇩🇪
Research SIte, Hann, Germany
🇬🇧Research Site, Wokingham, United Kingdom
A Study in People With Mild Hypertension
- Conditions
- First Posted Date
- 2006-09-12
- Last Posted Date
- 2007-05-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 153
- Registration Number
- NCT00374855
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Stockholm, Sweden
A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly
- Conditions
- Interventions
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2011-03-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 901
- Registration Number
- NCT00368277
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Study to Evaluate the Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled on Monotherapy
- Conditions
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 894
- Registration Number
- NCT00327145
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)
- Conditions
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 582
- Registration Number
- NCT00311740
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Tokyo, Japan
Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.
- Conditions
- First Posted Date
- 2006-03-24
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 388
- Registration Number
- NCT00306696
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo
- Conditions
- Interventions
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- Umeå University
- Target Recruit Count
- 26
- Registration Number
- NCT00282178
- Locations
- 🇸🇪
Umeå University Hospital, Umeå, Sweden
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2011-06-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 300
- Registration Number
- NCT00277472
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.